The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2025

Filed:

Oct. 26, 2018
Applicant:

Miltenyi Biotec B.v. & Co. KG, Bergisch Gladbach, DE;

Inventors:

Thomas Schaser, Rosrath, DE;

Nicole Cordes, Cologne, DE;

Joerg Mittelstaet, Cologne, DE;

Andrew Kaiser, Rosrath, DE;

Assignee:

MILTENYI BIOTEC B.V. & CO. KG, Bergisch Gladbach, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C07K 14/005 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); C07K 14/005 (2013.01); C07K 14/70503 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2740/10045 (2013.01); C12N 2740/16045 (2013.01);
Abstract

The present invention provides a composition comprising i) a pseudotyped retroviral vector particle or virus-like particle thereof comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its native receptor(s) and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for a tag of a tagged polypeptide, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, and b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and ii) said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of a target cell, thereby transducing the target cell with said retroviral vector particle or thereby inducing uptake of the virus-like particle into the target cell. A pharmaceutical composition thereof and an in vitro method for transduction of targets cells with said vector particle are also disclosed.


Find Patent Forward Citations

Loading…